|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL17RD |
Gene summary for IL17RD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL17RD | Gene ID | 54756 |
| Gene name | interleukin 17 receptor D | |
| Gene Alias | HH18 | |
| Cytomap | 3p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0001837 | UniProtAcc | Q8NFM7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54756 | IL17RD | HCC1 | Human | Liver | HCC | 1.90e-17 | 2.75e+00 | 0.5336 |
| 54756 | IL17RD | HCC2 | Human | Liver | HCC | 8.14e-20 | 1.22e+00 | 0.5341 |
| 54756 | IL17RD | HCC5 | Human | Liver | HCC | 7.96e-12 | 1.04e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007155921 | Liver | HCC | response to transforming growth factor beta | 141/7958 | 256/18723 | 3.08e-05 | 3.16e-04 | 141 |
| GO:007156021 | Liver | HCC | cellular response to transforming growth factor beta stimulus | 137/7958 | 250/18723 | 5.47e-05 | 5.14e-04 | 137 |
| GO:000717921 | Liver | HCC | transforming growth factor beta receptor signaling pathway | 106/7958 | 198/18723 | 1.09e-03 | 6.23e-03 | 106 |
| GO:19038442 | Liver | HCC | regulation of cellular response to transforming growth factor beta stimulus | 72/7958 | 131/18723 | 2.65e-03 | 1.27e-02 | 72 |
| GO:001701511 | Liver | HCC | regulation of transforming growth factor beta receptor signaling pathway | 70/7958 | 128/18723 | 3.56e-03 | 1.59e-02 | 70 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL17RD | SNV | Missense_Mutation | c.1104N>C | p.Gln368His | p.Q368H | Q8NFM7 | protein_coding | tolerated(0.14) | possibly_damaging(0.64) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IL17RD | SNV | Missense_Mutation | rs139866451 | c.481N>A | p.Val161Ile | p.V161I | Q8NFM7 | protein_coding | tolerated(0.07) | possibly_damaging(0.58) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL17RD | SNV | Missense_Mutation | c.1792G>C | p.Glu598Gln | p.E598Q | Q8NFM7 | protein_coding | deleterious_low_confidence(0.04) | benign(0.174) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IL17RD | SNV | Missense_Mutation | c.1152C>G | p.Phe384Leu | p.F384L | Q8NFM7 | protein_coding | deleterious(0.03) | possibly_damaging(0.861) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IL17RD | SNV | Missense_Mutation | rs751884613 | c.1432N>A | p.Val478Ile | p.V478I | Q8NFM7 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| IL17RD | insertion | Frame_Shift_Ins | novel | c.1986_1987insTATCT | p.Gly663TyrfsTer18 | p.G663Yfs*18 | Q8NFM7 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| IL17RD | insertion | Frame_Shift_Ins | novel | c.1984_1985insG | p.Ser662CysfsTer5 | p.S662Cfs*5 | Q8NFM7 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| IL17RD | SNV | Missense_Mutation | rs577890523 | c.676G>A | p.Gly226Ser | p.G226S | Q8NFM7 | protein_coding | deleterious(0.01) | probably_damaging(0.916) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL17RD | SNV | Missense_Mutation | rs753111564 | c.260N>T | p.Ala87Val | p.A87V | Q8NFM7 | protein_coding | tolerated(0.07) | benign(0.355) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| IL17RD | SNV | Missense_Mutation | rs200773591 | c.715N>A | p.Glu239Lys | p.E239K | Q8NFM7 | protein_coding | tolerated(0.14) | possibly_damaging(0.771) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |